Category: <span>FDA</span>

Category: FDA

Aduro Biotech, CRS-207, Dr. Thierry Jahan, FDA, Immunotherapy drug, malignant pleural mesothelioma, mesothelioma, mesothelioma clinical trial, Mesothelioma News, Orphan Drug Designation, U.S. Food and Drug Administration

Promising Clinical Trial Results For A Mesothelioma Immunotherapy Drug

 

Promising results from another phase of a clinical trial for an immunotherapy drug for mesothelioma, CRS-207, have been released.

CimaVax Vaccine, Cuba's Center for Molecular Immunology, Dr. Candace Johnson, FDA, Gal Shafirstein, Governor Andrew Cuomo, mesothelioma cancer, Mesothelioma News, National Cancer Institute, PDT, Photodynamic Therapy, Roswell Park Cancer Institute, U.S. Food and Drug Administration

Promising Lung Cancer Vaccine From Cuba At Roswell Park Cancer Institute

 

Roswell Park Cancer Institute is working on a promising lung cancer vaccine from Cuba that will be submitted for FDA approval.

Dako North America Inc., Dr. Richard Pazdur, Dr. Roger M. Perlmutter, FDA, Immunotherapy, Keytruda, Merck, mesothelioma cancer, Mesothelioma News, Non-small cell lung cancer, NSCLC, PD-L1, U.S. Food and Drug Administration

FDA-Approved Keytruda Treatment Could Help Mesothelioma Patients

 

Recently, the FDA approved Merck immunotherapy drug Keytruda for treatment in non-small cell lung cancer and is bringing hope to mesothelioma patients.

anti-CTLA-4, Anti-PD-1, Anti-PD-L1, Apoptosis, Dickkpf-3, FDA, Hypermethylation, Immuno-oncology, Immunotherapy, Mesothelioma News, MTG Biotherapeutics, MTG-201, Okayama Medical Hospital, Orphan Drug Designation, Premetrexed, Reduced Expression in Immortalized Cells, REIC, Rob Lowenthal, T-cell lymphocytes, US Food and Drug Administration

New Mesothelioma Treatment Receives FDA Orphan Drug Designation

 

A new drug has been granted Orphan Drug Status by the US FDA as a potentially safe and effective treatment for mesothelioma cancer.

anti-CTLA-4, AstraZeneca, FDA, ipilimumab, Malignant mesothelioma, mesothelioma, Mesothelioma News, Orphan Drug, Orphan Drug Act of January 1983, Robert Iannone, tremelimumab

FDA Grants AstraZeneca’s Tremelimumab Orphan Drug Status for Mesothelioma

 

AstraZeneca’s tremelimumab (anti-CTLA-4 monoclonal antibody) has received Orphan Drug status from the FDA for treating malignant mesothelioma.

Bristol-Myers Squibb, Dr. Richard Pazdur, Dr. Roy Herbst, Dr. Scott Gettinger, FDA, Immunotherapy, Keytruda, Merck, mesothelioma, Mesothelioma News, Mesothelioma treatment, Opdivo

Can Opdivo Drug Be Good News for Mesothelioma Patients?

 

Expanded approved use of new lung cancer drug Opdivo could give malignant pleural mesothelioma patients hope.